Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors
Globe Newswire (Tue, 7-Apr 8:30 AM ET)
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 6-Apr 8:30 AM ET)
Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York
Globe Newswire (Thu, 2-Apr 8:30 AM ET)
Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates
Globe Newswire (Tue, 17-Mar 7:30 AM ET)
Globe Newswire (Mon, 9-Mar 7:30 AM ET)
Globe Newswire (Tue, 3-Mar 7:30 AM ET)
Abeona Expands Access to ZEVASKYN in Texas: UTMB Galveston Now a Qualified Treatment Center
Market Chameleon (Thu, 11-Dec 3:36 AM ET)
Market Chameleon (Mon, 8-Dec 3:21 AM ET)
Market Chameleon (Mon, 13-Oct 4:19 AM ET)
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Abeona Therapeutics trades on the NASDAQ stock market under the symbol ABEO.
As of April 22, 2026, ABEO stock price climbed to $5.54 with 257,432 million shares trading.
ABEO has a beta of 1.85, meaning it tends to be more sensitive to market movements. ABEO has a correlation of 0.19 to the broad based SPY ETF.
ABEO has a market cap of $316.05 million. This is considered a Small Cap stock.
Last quarter Abeona Therapeutics reported $5 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $503,400 and exceeded earnings estimates by $.02.
In the last 3 years, ABEO traded as high as $9.01 and as low as $2.83.
The top ETF exchange traded funds that ABEO belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ABEO has underperformed the market in the last year with a return of +12.6%, while SPY returned +39.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABEO shares. However, ABEO has outperformed the market in the last 3 month and 2 week periods, returning +4.3% and +15.2%, while SPY returned +3.8% and +7.6%, respectively. This indicates ABEO has been having a stronger performance recently.
ABEO support price is $5.21 and resistance is $5.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABEO shares will trade within this expected range on the day.